# MB-105 in Patients With CD5 Positive T-cell Lymphoma

> **NCT06534060** · PHASE2 · RECRUITING · sponsor: **March Biosciences Inc** · enrollment: 46 (estimated)

## Conditions studied

- Lymphoma, T-Cell

## Interventions

- **BIOLOGICAL:** Genetic: MB-105

## Key facts

- **NCT ID:** NCT06534060
- **Lead sponsor:** March Biosciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-15
- **Primary completion:** 2028-02
- **Final completion:** 2029-12
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06534060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06534060, "MB-105 in Patients With CD5 Positive T-cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06534060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*